Concomitantly targeting AURK and FLT3 exhibited potent cytotoxicity with lower half-maximal inhibitory concentrations (IC50s) values against FLT3-ITD-mutant MV4–11, MOLM13 and MOLM13-resistant AML cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.